El inhibidor de FGFR de Johnson & Johnson, erdafitinib es aprobado para su comercialización en China

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Erdafitinib #Balversa #JohnsonAndJohnson #FGFR #FGFR3 #UrothelialCarcinoma #Oncología

First treatment for common bladder cancer recommended by NICE - PharmaTimes Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration

#bladdercancer #NICErecommended #JnJ #Balversa #urothelialcancer #geneticalteration #erdafitinib #FGFR3alteration #unresectableurothelialcancer #metastaticurothelialcancer #THOrclinicaltrial #FGFR3expressingcancercellgrowth #genetictesting
pharmatimes.com/news/first-t...